Glycerophospholipids and glycerophospholipid-derived lipid mediators: A complex meshwork in Alzheimer's disease pathology

Progress in Lipid Research

Volumn 50, Issue 4, 2011, Pages 313-330

  Frisardi, Vincenza ^a   Panza, Francesco ^b   Seripa, Davide ^b   Farooqui, Tahira ^c   Farooqui, Akhlaq A ^c  

^a UNIVERSITY OF BARI   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Arachidonic acid; Dementia; Diet; Docosahexaenoic acid; Docosanoids; Eicosanoids; Endocannabinoids; Glycerophospholipids; Lipid mediators; Lysophosphatidylcholine; Platelet activating factor; Polyunsaturated fatty acids

Indexed keywords

4 HYDROXYNONENAL; ACROLEIN; ARACHIDONIC ACID; CANNABINOID; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; GLYCOPHOSPHOLIPID; ICOSANOID; ISOFURAN; ISOKETAL; ISOPROSTANE DERIVATIVE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHOLIPID; MALONALDEHYDE; NEUROFURAN; NEUROKETAL; NEUROPROSTANE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; POLYUNSATURATED FATTY ACID; REACTIVE OXYGEN METABOLITE; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; APOPTOSIS; BRAIN TISSUE; CAUSAL ATTRIBUTION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME METABOLISM; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; LIPID METABOLISM; LIPOGENESIS; NERVE DEGENERATION; NERVE MEMBRANE; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR;

ALDEHYDES; ALZHEIMER DISEASE; ARACHIDONIC ACIDS; BRAIN; CANNABINOIDS; DIETARY FATS; DOCOSAHEXAENOIC ACIDS; FATTY ACIDS, UNSATURATED; GLYCEROPHOSPHOLIPIDS; HUMANS; LIPID METABOLISM; LYSOPHOSPHOLIPIDS; OXIDATION-REDUCTION; PHOSPHOLIPASES A2; PLATELET ACTIVATING FACTOR; REACTIVE OXYGEN SPECIES;

EID: 79959858679     PISSN: 01637827     EISSN: 18732194     Source Type: Journal    
DOI: 10.1016/j.plipres.2011.06.001     Document Type: Review

References (266)

1. O. Quehenberger, A.M. Armando, A.H. Brown, S.B. Milne, D.S. Myers, and A.H. Merrill Lipidomics reveals a remarkable diversity of lipids in human plasma J Lipid Res 51 2010 3299 3305
2. V. Frisardi, V. Solfrizzi, P.B. Imbimbo, C. Capurso, A. D'Introno, and A.M. Colacicco Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid Curr Alzheimer Res 7 2010 40 55
3. V. Frisardi, V. Solfrizzi, D. Seripa, A. Pilotto, and F. Panza Plasma lipid disturbances, inflammation, and cognitive decline J Am Geriatr Soc 58 2010 2429 2430
4. Alzheimer's Association Alzheimer's disease facts and figures Alzheimers Dement 6 2010 158 194
5. R. Brookmeyer, E. Johnson, K. Ziegler-Graham, and H.M. Arrighi Forecasting the global burden of Alzheimer's disease Alzheimers Dement 3 2007 186 191 (Pubitemid 46825511)
6. B. De Strooper Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process Physiol Rev 90 2010 465 494
7. R. Takechi, S. Galloway, M.M.S. Pallebage-Gamarallage, V. Lam, and J.C.L. Mamo Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk Prog Lipid Res 49 2010 159 170
8. D.A. Butterfield, T. Reed, S.F. Newman, and R. Sultana Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment Free Radic Biol Med 43 2007 658 677 (Pubitemid 47102132)
9. C. Holmes, D. Boche, D. Wilkinson, G. Yadegarfar, V. Hopkins, and A. Bayer Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial Lancet 372 2008 216 223 (Pubitemid 351978111)
10. B.P. Imbimbo, F. Panza, V. Frisardi, V. Solfrizzi, G. D'Onofrio, and G. Logroscino Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? Expert Opin Investig Drugs 20 2011 325 412
11. R.J. Castellani, H.G. Lee, S.L. Siedlak, A. Nunomura, T. Hayashi, and M. Nakamura Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta J Alzheimers Dis 18 2009 447 452
12. P. Foley Lipids in Alzheimer's disease: a century-old story Biochim Biophys Acta 1801 2010 750 753
13. Y. Sugiura, Y. Konishi, N. Zaima, S. Kajihara, H. Nakanishi, and R. Taguchi Visualization of the cell-selective distribution of PUFA-containing phosphatidylcholines in mouse brain by imaging mass spectrometry J Lipid Res 50 2009 1776 1788
14. J.M. Dietschy, and S.D. Turley Cholesterol metabolism in the brain Curr Opin Lipidol 12 2001 105 112 (Pubitemid 32242918)
15. A.A. Farooqui, W.Y. Ong, and T. Farooqui Lipid mediators in the nucleus: their potential contribution to Alzheimer's disease Biochim Biophys Acta 1801 2010 906 916
16. R. Nitsch, A. Pittas, J.K. Blusztajn, B.E. Slack, J.H. Growdon, and R.J. Wurtman Alterations of phospholipid metabolites in postmortem brain from patients with Alzheimer's disease Ann NY Acad Sci 640 1991 110 113
17. C. Mulder, L.O. Wahlund, T. Teerlink, M. Blomberg, R. Veerhuis, and G.J. van Kamp Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease J Neural Transm 110 2003 949 955 (Pubitemid 36981409)
18. V. Frisardi, F. Panza, D. Seripa, B.P. Imbimbo, G. Vendemiale, and A. Pilotto Nutraceutical properties of Mediterranean diet and cognitive decline: possible underlying mechanisms J Alzheimers Dis 22 2010 715 740
19. E. Fahy, S. Subramaniam, R.C. Murphy, M. Nishijima, C.R. Raetz, and T. Shimizu Update of the LIPID MAPS comprehensive classification system for lipids J Lipid Res 50 Suppl 2009 S9 S14
20. G. Porcellati Phospholipid metabolism in neural membranes G.Y. Sun, N. Bazan, J.Y. Wu, G. Porcellati, A.Y. Sun, Neural membranes 1983 Humana Press New York 3 35
21. A.A. Farooqui, and L.A. Horrocks Metabolic and functional aspects of neural membrane phospholipids L.A. Horrocks, J.N. Kanfer, G. Porcellati, Phospholipids in the nervous system Physiological role vol. II 1985 Raven Press New York 341 348
22. H. Palsdottir, and C. Hunte Lipids in membrane protein structures Biochim Biophys Acta 1666 2004 2 18 (Pubitemid 39425195)
23. A.A. Farooqui, and L.A. Horrocks Glycerophospholipids in the brain: phospholipases A2 in neurological disorders 2007 Springer New York p. 1-394
24. A.A. Farooqui Neural membranes: a Pandora's box of lipid mediators Hot topics in neural membrane lipidology 2009 Springer New York p. 1-36
25. N.G. Bazan Lipid signaling in neural plasticity, brain repair, and neuroprotection Mol Neurobiol 32 2005 89 103 (Pubitemid 41113211)
26. N.G. Bazan Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress Brain Pathol 15 2005 159 166 (Pubitemid 40546172)
27. N.G. Bazan Synaptic signaling by lipids in the life and death of neurons Mol Neurobiol 31 2005 219 230 (Pubitemid 41271205)
28. C.N. Serhan Novel ω-3-derived local mediators in anti-inflammation and resolution Pharmacol Ther 105 2005 7 21
29. C.N. Serhan, and J. Savill Resolution of inflammation: the beginning programs the end Nature Immunol 6 2005 1191 1197 (Pubitemid 43045627)
30. J.W. Phillis, L.A. Horrocks, and A.A. Farooqui Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders Brain Res Rev 52 2006 201 243 (Pubitemid 44291802)
31. Farooqui AA. Metabolism and role of eicosanoids in the brain in lipid mediators in the brain: the good, the bad, and the ugly. New York: Springer; in press.
32. A.P. Simopoulos Omega-3 fatty acids in inflammation and autoimmune diseases J Am Coll Nutr 21 2002 495 505 (Pubitemid 36026261)
33. L.A. Horrocks, and A.A. Farooqui Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function Prostaglandins Leukot Essent Fatty Acids 70 2004 361 372 (Pubitemid 38429269)
34. A.A. Farooqui Perspective and directions for future development on the effects of fish oil constituents on brain Beneficial effects of fish oil on human brain 2009 Springer Berlin p. 367-84
35. P. Montuschi, P. Barnes, and L.J. Roberts 2nd Insights into oxidative stress: the isoprostanes Curr Med Chem 14 2007 703 717 (Pubitemid 46477722)
36. T. Oster, and T. Pillot Docosahexaenoic acid and synaptic protection in Alzheimer's disease mice Biochim Biophys Acta 1801 2010 791 798
37. E. Hogyes, C. Nykas, T. Kiliaan, T. Farkas, B. Penke, and P.G.M. Luiten Neuroprotective effect of developmental docosahexaenoic acid supplement against excitotoxic brain damage in infant rats Neuroscience 119 2003 999 1012 (Pubitemid 36776450)
38. A.A. Farooqui, W.Y. Ong, L.A. Horrocks, P. Chen, and T. Farooqui Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans Brain Res Rev 56 2007 443 471 (Pubitemid 350166530)
39. A.P. Simopoulos The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases Exp Biol Med (Maywood) 233 2008 674 688
40. A.A. Farooqui Neurochemical aspects of neurodegenerative diseases Neurochemical aspects of neurotraumatic and neurodegenerative diseases 2010 Springer New York pp. 249-324
41. C.E. Stokes, and J.N. Hawthorne Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains J Neurochem 48 1987 1018 1021 (Pubitemid 18001319)
42. M. Söderberg, C. Edlund, K. Kristensson, and G. Dallner Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease Lipids 26 1991 421 425
43. K. Wells, A.A. Farooqui, L. Liss, and L.A. Horrocks Neural membrane phospholipids in Alzheimer disease Neurochem Res 20 1995 1329 1333 (Pubitemid 26003436)
44. Z. Guan, Y. Wang, N.J. Cairns, P.L. Lantos, G. Dallner, and P.J. Sindelar Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease J Neuropathol Exp Neurol 58 1999 740 747 (Pubitemid 29328503)
45. X. Han, D.M. Holtzman, and D.W. McKeel Jr. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry J Neurochem 77 2001 1168 1180 (Pubitemid 32467071)
46. J.W. Pettegrew, K. Panchalingam, R.L. Hamilton, and R.J. McClure Brain membrane phospholipid alterations in Alzheimer's disease Neurochem Res 26 2001 771 782 (Pubitemid 32845968)
47. M. Igarashi, K. Ma, F. Gao, H.W. Kim, S.I. Rapoport, and J.S. Rao Disturbed choline plasmalogen and phospholipid fatty acid concentrations in Alzheimer's disease prefrontal cortex J Alzheimers Dis 2011 10.3233/JAD-2011- 101608
48. A.A. Farooqui, S.I. Rapoport, and L.A. Horrocks Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens Neurochem Res 22 1997 523 527 (Pubitemid 27184719)
49. D. Stephenson, K. Rash, B. Smalstig, E. Roberts, E. Johnstone, and J. Sharp Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration Glia 27 1999 110 128 (Pubitemid 29365748)
50. A.A. Farooqui, W.Y. Ong, and L.A. Horrocks Plasmalogens, docosahexaenoic acid and neurological disorders Adv Exp Med Biol 544 2003 335 354 (Pubitemid 38331975)
51. J.N. Kanfer, G. Sorrentino, and D.S. Sitar Phospholipases as mediators of amyloid beta peptide neurotoxicity: an early event contributing to neurodegeneration characteristic of Alzheimer's disease Neurosci Lett 257 1998 93 96 (Pubitemid 28552896)
52. C. Malaplate-Armand, S. Florent-Béchard, I. Youssef, V. Koziel, I. Sponne, and B. Kriem Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway Neurobiol Dis 23 2006 178 189 (Pubitemid 43922461)
53. B. Kriem, I. Sponne, A. Fifre, C. Malaplate-Armand, K. Lozac'h-Pillot, and V. Koziel Cytosolic phospholipase A2 mediates neuronal apoptosis induced by soluble oligomers of the amyloid-beta peptide FASEB J 19 2005 85 87 (Pubitemid 40069926)
54. G.Y. Sun, J. Xu, M.D. Jensen, and A. Simonyi Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases J Lipid Res 45 2004 205 213 (Pubitemid 38228817)
55. D. Wissing, H. Mouritzen, M. Egeblad, G.G. Poirer, and M. Jaattela Involvement of caspase-dependent activation of cytosolic phospholipase A2 in tumor necrosis factor-induced apoptosis Proc Natl Acad Sci USA 94 1997 5073 5077 (Pubitemid 27214738)
56. S. Jayadev, H.L. Hayter, N. Andrieu, C.J. Gamard, B. Liu, and R. Balu Phospholipase A2 is necessary for tumor necrosis factor α-induced ceramide generation in L929 cells J Biol Chem 272 1997 17196 17203 (Pubitemid 27289833)
57. B.J. Pettus, A. Bielawska, P. Subramanian, D.S. Wijesinghe, M. Maceyka, and C.C. Leslie Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2 J Biol Chem 279 2004 11320 11326 (Pubitemid 38401629)
58. B.J. Pettus, K. Kitatani, C.E. Chalfant, T.A. Taha, T. Kawamori, and J. Bielawski The coordination of prostaglandin E2 production by sphingosine-1-phosphate and ceramide-1-phosphate Mol Pharmacol 68 2005 330 335 (Pubitemid 41058296)
59. R.G. Cutler, J. Kelley, K. Storie, W.A. Pedersen, A. Tammara, and K. Hatanpaa Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease Proc Natl Acad Sci 101 2004 2070 2075 (Pubitemid 38229016)
60. X. He, Y. Huang, B. Li, C.X. Gong, and E.H. Schuchman Deregulation of sphingolipid metabolism in Alzheimer's disease Neurobiol Aging 31 2010 398 408
61. M.K. O'Banion Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology Crit Rev Neurobiol 13 1999 45 82 (Pubitemid 29231727)
62. A.A. Farooqui Studies on plasmalogen-selective phospholipase A2 in brain Mol Neurobiol 41 2010 267 273
63. J.R. Vane, and Y.S. Bakhle Botting RM Cyclooxygenases 1 and 2 Annu Rev Pharmacol Toxicol 38 1998 97 120
64. S. Hong, K. Gronert, P.R. Devchand, and R.L. Moussignac Serhan CN Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation J Biol Chem 278 2003 14677 14687 (Pubitemid 36799790)
65. V.L. Marcheselli, S. Hong, W.J. Lukiw, X.H. Tian, K. Gronert, and A. Musto Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression J Biol Chem 278 2003 43807 43817 (Pubitemid 37346009)
66. C.N. Serhan, R. Yang, K. Martinod, K. Kasuga, P.S. Pillai, and T.F. Porter Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions J Exp Med 206 2009 15 23
67. N.G. Bazan Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor J Lipid Res 44 2003 2221 2233 (Pubitemid 38082480)
68. J.C. Demar Jr., H.J. Lee, L. Chang, J.M. Bell, S.I. Rapoport, and R.P. Bazinet Brain elongation of linoleic acid is a negligible source of the arachidonate in brain phospholipids of adult rats Biochim Biophys Acta 1761 2006 1050 1059 (Pubitemid 44354290)
69. C.T. Chen, J.T. Green, S.K. Orr, and R.P. Bazinet Regulation of brain polyunsaturated fatty acid uptake and turnover Prostaglandins Leukot Essent Fatty Acids 79 2008 85 91
70. C.T. Chen, D.W. Ma, J.H. Kim, H.T. Mount, and R.P. Bazinet The low density lipoprotein receptor is not necessary for maintaining mouse brain polyunsaturated fatty acid concentrations J Lipid Res 49 2008 147 152
71. S.I. Rapoport, J.S. Rao, and M. Igarashi Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver Prostaglandins Leukot Essent Fatty Acids 77 2007 251 261 (Pubitemid 350214520)
72. Y. Qu, L. Chang, J. Klaff, A. Balbo, and S.I. Rapoport Imaging brain phospholipase A2 activation in awake rats in response to the5-HT2A/2C agonist (+/-)2,5-dimethoxy-4-iodophenyl-2 aminopropane(DOI) Neuropsychopharmacology 28 2003 244 252
73. M. Basselin, L. Chang, J.M. Bell, and S.I. Rapoport Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats Neuropsychopharmacology 31 2006 1659 1674 (Pubitemid 44106697)
74. A.K. Bhattacharjee, L. Chang, H.J. Lee, R.P. Bazinet, R. Seemann, and S.I. Rapoport D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats Psychopharmacology 180 2005 735 742 (Pubitemid 41317869)
75. M. Basselin, L. Chang, R. Seemann, J.M. Bell, and S.I. Rapoport Chronic lithium administration potentiates brain arachidonic acid signaling at rest and during cholinergic activation in awake rats J Neurochem 85 2003 1553 1562 (Pubitemid 36702567)
76. 2+ Br J Pharmacol 139 2003 1014 1022 (Pubitemid 36877400)
77. R.P. Bazinet Is the brain arachidonic acid cascade a common target of drugs used to manage bipolar disorder? Biochem Soc Trans 37 2009 1104 1109
78. A.A. Farooqui, L.A. Horrocks, and T. Farooqui Interactions between neural membrane glycerophospholipid and sphingolipid mediators: a recipe for neural cell survival or suicide J Neurosci Res 85 2007 1834 1850 (Pubitemid 47051473)
79. Y.L. Niu, W.J. Zhang, P. Wu, B. Liu, G.T. Sun, and D.M. Yu Expression of the apoptosis-related proteins caspase-3 and NF-kappaB in the hippocampus of Tg2576 mice Neurosci Bull 26 2010 37 46
80. E.L. Schaeffer, and W.F. Gattaz Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme Psychopharmacology 198 2008 1 27
81. R. Anwyl Metabotropic glutamate receptor-dependent long-term potentiation Neuropharmacology 56 2009 735 740
82. J.F. Macdonald, M.F. Jackson, and M.A. Beazely Hippocampal long-term synaptic plasticity and signal amplification of NMDA receptors Crit Rev Neurobiol 18 2006 71 84 (Pubitemid 350194079)
83. G. Goracci, M. Ferrini, and V. Nardicchi Low molecular weight phospholipases A2 in mammalian brain and neural cells: roles in functions and dysfunctions Mol Neurobiol 41 2010 274 289
84. K. Arai, Y. Ikegaya, Y. Nakatani, I. Kudo, N. Nishiyama, and N. Matsuki Phospholipase A2 mediates ischemic injury in the hippocampus: a regional difference of neuronal vulnerability Eur J Neurosci 13 2001 2319 2323 (Pubitemid 32664318)
85. J.W. Phillis, and M.H. O'Regan Mechanisms of glutamate and aspartate release in the ischemic rat cerebral cortex Brain Res 730 1996 150 164 (Pubitemid 26305335)
86. E. Chiricozzi, S. Fernandez-Fernandez, V. Nardicchi, A. Almeida, J.P. Bolaños, and G. Goracci Group IIA secretory phospholipase A2 (GIIA) mediates apoptotic death during NMDA receptor activation in rat primary cortical neurons J Neurochem 112 2010 1574 1583
87. K. Kishimoto, R.C. Li, J. Zhang, J.A. Klaus, K.K. Kibler, and S. Doré Cytosolic phospholipase A2 alpha amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice J Neuroinflammation 7 2010 42
88. P.N. Alexandrov, J.G. Cui, and W.J. Lukiw Hypoxia-sensitive domain in the human cytosolic phospholipase A2 promoter Neuroreport 17 2006 303 307
89. A. Alessandrini, S. Namura, M.A. Moskowitz, and J.V. Bonventre MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia Proc Natl Acad Sci USA 96 1999 12866 12869 (Pubitemid 29513594)
90. E. Paine, R. Palmantier, S.K. Akiyama, K. Olden, and J.D. Roberts Arachidonic acid activates mitogen-activated protein (MAP) kinase-activated protein kinase 2 and mediates adhesion of a human breast carcinoma cell line to collagen type IV through a p38 MAP kinase-dependent pathway J Biol Chem 275 2000 11284 11290 (Pubitemid 30212776)
91. J.A. Claassen, R. Diaz-Arrastia, K. Martin-Cook, B.D. Levine, and R. Zhang Altered cerebral hemodynamics in early Alzheimer disease: a pilot study using transcranial Doppler J Alzheimers Dis 17 2009 621 629
92. W. Dai, O.L. Lopez, O.T. Carmichael, J.T. Becker, L.H. Kuller, and H.M. Gach Mild cognitive impairment and alzheimer disease: patterns of altered cerebral blood flow at MR imaging Radiology 250 2009 856 866
93. D.T. Stephenson, C.A. Lemere, D.J. Selkoe, and J.A. Clemens Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain Neurobiol Dis 3 1996 51 63 (Pubitemid 26145405)
94. V. Colangelo, J. Schurr, M.J. Ball, R.P. Pelaez, N.G. Bazan, and W.J. Lukiw Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling J Neurosci Res 70 2002 462 473 (Pubitemid 35222383)
95. P.J. Cimino, C.D. Keene, R.M. Breyer, K.S. Montine, and T.J. Montine Therapeutic targets in prostaglandin E2 signaling for neurologic disease Curr Med Chem 15 2008 1863 1869
96. K. Yamagata, K.I. Andreasson, W.E. Kaufmann, C.A. Barnes, and P.F. Worley Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids Neuron 11 1993 371 386 (Pubitemid 23250354)
97. O. Pepicelli, E. Fedele, M. Berardi, M. Raiteri, G. Levi, and A. Greco Cyclo-oxygenase-1 and -2 differently contribute to prostaglandin E2 synthesis and lipid peroxidation after in vivo activation of N-methyl-d-aspartate receptors in rat hippocampus J Neurochem 93 2005 1561 1567 (Pubitemid 40853279)
98. S.J. Hewett, T.F. Uliasz, A.S. Vidwans, and J.A. Hewett Cyclooxygenase-2 contributes to N-methyl-d-aspartate-mediated neuronal cell death in primary cortical cell culture J Pharmacol Exp Ther 293 2000 417 425 (Pubitemid 30244090)
99. C. Iadecola, K. Niwa, S. Nogawa, X. Zhao, M. Nagayama, and E. Araki Reduced susceptibility to ischemic brain injury and N-methyl-d-aspartate- mediated neurotoxicity in cyclooxygenase-2-deficient mice Proc Natl Acad Sci USA 98 2001 1294 1299 (Pubitemid 32121226)
100. T. Kawano, J. Anrather, P. Zhou, L. Park, G. Wang, and K.A. Frys Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity Nat Med 12 2006 225 229 (Pubitemid 43214750)
101. D. Liu, L. Wu, R. Breyer, M.P. Mattson, and K. Andreasson Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia Ann Neurol 57 2005 758 761 (Pubitemid 40628868)
102. M. Bilak, L. Wu, Q. Wang, N. Haughey, K. Conant, and C. St Hillaire PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis Ann Neurol 56 2004 240 248 (Pubitemid 39037919)
103. B.S. Berlett, and E.R. Stadtman Protein oxidation in aging, disease, and oxidative stress J Biol Chem 272 1997 20313 20316 (Pubitemid 27355575)
104. G.M. Pasinetti, and P.S. Aisen Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain Neuroscience 87 1998 319 324 (Pubitemid 28370892)
105. W.P. Qin, L. Ho, P.N. Pompl, Y.Z. Peng, Z. Zhao, and Z.M. Xiang Cyclooxygenase (COX)-2 and COX-1 potentiate β-amyloid peptide generation through mechanisms that involve γ-secretase activity J Biol Chem 278 2003 50970 50977 (Pubitemid 38020330)
106. N.G. Bazan, V. Colangelo, and W.J. Lukiw Prostaglandins and other lipid mediators in Alzheimer's disease Prostaglandins Other Lipid Mediat 68-69 2002 197 210 (Pubitemid 35247397)
107. M.D. Ikonomovic, E.E. Abrahamson, T. Uz, H. Manev, and S.T. Dekosky Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease J Histochem Cytochem 56 2008 1065 1073
108. J.J. Hoozemans, and M.K. O'Banion The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs Curr Drug Targets CNS Neurol Disord 4 2005 307 315 (Pubitemid 40754165)
109. J.J. Hoozemans, J.M. Rozemuller, E.S. van Haastert, R. Veerhuis, and P. Eikelenboom Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology Curr Pharm Des 14 2008 1419 1427 (Pubitemid 351982549)
110. Z. Xiang, L. Ho, J. Valdellon, D. Borchelt, K. Kelley, and L. Spielman Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology Neurobiol Aging 23 2002 327 334 (Pubitemid 34312015)
111. K.J. Kwon, Y.S. Jung, S.H. Lee, C.H. Moon, and E.J. Baik Arachidonic acid induces neuronal death through lipoxygenase and cytochrome P450 rather than cyclooxygenase J Neurosci Res 81 2005 73 84 (Pubitemid 41139112)
112. G. Halliday, S.R. Robinson, C. Shepherd, and J. Kril Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms Clin Exp Pharmacol Physiol 27 2000 1 8 (Pubitemid 30104083)
113. M.T. Heneka, and M.K. O'Banion Inflammatory processes in Alzheimer's disease J Neuroimmunol 184 2007 69 91 (Pubitemid 46365992)
114. K.M. Hayden, P.P. Zandi, A.S. Khachaturian, C.A. Szekely, M. Fotuhi, and M.C. Norton Cache County investigators. Does NSAID use modify cognitive trajectories in the elderly? The Cache County study Neurology 69 2007 275 282 (Pubitemid 47205690)
115. B.P. Imbimbo, V. Solfrizzi, and F. Panza Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front Aging Neurosci 2 2010 19
116. C.G. Lyketsos, J.C. Breitner, R.C. Green, B.K. Martin, C. Meinert, and S. Piantadosi Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trialm Neurology 68 2007 1800 1808 (Pubitemid 46791392)
117. B.K. Martin, C. Szekely, J. Brandt, S. Piantadosi, J.C. Breitner, and S. Craft Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib Arch Neurol 65 2008 896 905 (Pubitemid 352008472)
118. J.C. Breitner, S.J. Haneuse, R. Walker, S. Dublin, P.K. Crane, and S.L. Gray Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort Neurology 72 2009 1899 1905
119. S.R. Salpeter, P. Gregor, T.M. Ormiston, R. Whitlock, P. Raina, and L. Thabane Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs Am J Med 119 2006 552 559 (Pubitemid 44063485)
120. R.S. Bresalier, V.E. Friedewald Jr., R.E. Rakel, W.C. Roberts, and G.W. Williams The Editor's roundtable: cyclooxygenase-2 inhibitors and cardiovascular risk Am J Cardiol 96 2005 1589 1604 (Pubitemid 41690185)
121. P.T. Jantzen, K.E. Connor, G. DiCarlo, G. Wenk, J. Wallace, and A. Rojiani Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice Neuroscience 22 2002 2246 2254 (Pubitemid 35386524)
122. S. Weggen, J.L. Eriksen, S.A. Sagi, C.U. Pietrzik, V. Ozols, and A. Fauq Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity J Biol Chem 278 2003 31831 31837 (Pubitemid 37048365)
123. T.A. Lanz, G.J. Fici, and K.M. Merchant Lack of specific amyloid-beta(1-42) suppression by nonsteroidal anti-inflammatory drugs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures J Pharmacol Exp Ther 312 2005 399 406 (Pubitemid 40096494)
124. K. Fassbender, S. Walter, S. Kuhl, R. Landmann, K. Ishii, and T. Bertsch The LPS receptor (CD14) links innate immunity with Alzheimer's disease FASEB J 18 2004 203 205
125. F.S. Shie, R.M. Breyer, and T.J. Montine Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity Am J Pathol 166 2005 1163 1172 (Pubitemid 40524440)
126. V. Echeverria, A. Clerman, and S. Dore Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure Eur J Neurosci 22 2005 2199 2206 (Pubitemid 41653533)
127. S.C. Cunnane, M. Plourde, F. Pifferi, M. Bégin, C. Féart, and P. Barberger-Gateau Fish, docosahexaenoic acid and Alzheimer's disease Prog Lipid Res 48 2009 239 256
128. A. Ariel, and C.N. Serhan Resolvins and protectins in the termination program of acute inflammation Trends Immunol 28 2007 176 183 (Pubitemid 46467520)
129. C.N. Serhan, M. Arita, S. Hong, and K. Gotlinger Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers Lipids 2004 391125 391132
130. S. Hong, K. Gronert, P. Devchand, R.-L. Moussignac, and C.N. Serhan Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation J Biol Chem 278 2003 14677 14687 (Pubitemid 36799790)
131. C.N. Serhan, N. Chiang, and T.E. Van Dyke Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators Nat Rev Immunol 8 2008 349 361 (Pubitemid 351595216)
132. W.J. Lukiw, J.G. Cui, V.L. Marcheselli, M. Bodker, A. Botkjaer, and K. Gotlinger A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease J Clin Invest 115 2005 2774 2783 (Pubitemid 41434404)
133. N.G. Bazan Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease J Lipid Res 50 Suppl 2009 S400 S405
134. N.G. Bazan Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection Prostaglandins Leukot Essent Fatty Acids 81 2009 205 211
135. Y. Zhao, F. Calon, C. Julien, J.W. Winkler, N.A. Petasis, and W.J. Lukiw PLoS One 6 2011 e15816
136. G.A. Jicha, and W.R. Markesbery Omega-3 fatty acids: potential role in the management of early Alzheimer's disease Clin Interv Aging 5 2010 45 61
137. S.E. Perez, B.M. Berg, K.A. Moore, B. He, S.E. Counts, and J.J. Fritz DHA diet reduces AD pathology in young APPswe/PS1 Delta E9 transgenic mice: possible gender effects J Neurosci Res 88 2010 1026 1040
138. L. Guo, J. Duggan, and M.F. Cordeiro Alzheimer's disease and retinal neurodegeneration Curr Alzheimer Res 7 2010 3 14
139. E. Kirby, S. Bandelow, and E. Hogervorst Visual impairment in Alzheimer's disease: a critical review J Alzheimers Dis 21 2010 15 34
140. V. Martín, N. Fabelo, G. Santpere, B. Puig, R. Marín, and I. Ferrer Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex J Alzheimers Dis 19 2010 489 502
141. F. Calderon, and H.Y. Kim Role of RXR in neurite outgrowth induced by docosahexaenoic acid Prostaglandins Leukot Essent Fatty Acids 77 2007 227 232 (Pubitemid 350198865)
142. A.M. de Urquiza, S. Liu, M. Sjoberg, R.H. Zetterstrom, W. Griffiths, and J. Sjovall Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain Science 290 2000 2140 2144 (Pubitemid 32001593)
143. J. Lengqvist, A. Mata De Urquiza, A.C. Bergman, T.M. Willson, J. Sjovall, and T. Perlmann Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain Mol Cell Proteomics 3 2004 692 703 (Pubitemid 39077000)
144. N. Etchamendy, V. Enderlin, A. Marighetto, R.M. Vouimba, V. Pallet, and R. Jaffard Alleviation of a selective age-related relational memory deficit in mice by pharmacologically induced normalization of brain retinoid signaling J Neurosci 21 2001 6423 6429 (Pubitemid 32737774)
145. C. Feart, F. Mingaud, V. Enderlin, M. Husson, S. Alfos, and P. Higueret Differential effect of retinoic acid and triiodothyronine on the age-related hypo-expression of neurogranin in rat Neurobiol Aging 26 2005 729 738 (Pubitemid 40228765)
146. F. Mingaud, C. Mormede, N. Etchamendy, N. Mons, B. Niedergang, and M. Wietrzych Retinoid hyposignaling contributes toaging-related decline in hippocampal function in short-term/working memory organization and long-term declarative memory encoding in mice J Neurosci 28 2008 279 291
147. M. Tafti, and N.B. Ghyselinck Functional implication of the vitamin A signaling pathway in the brain Arch Neurol 64 2007 1706 1711 (Pubitemid 350254931)
148. A.B. Goodman Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset Alzheimer disease J Cell Physiol 209 2006 598 603 (Pubitemid 44665675)
149. A.B. Goodman, and A.B. Pardee Evidence for defective retinoid transport and function in late onset Alzheimer's disease Proc Natl Acad Sci USA 100 2003 2901 2905 (Pubitemid 36297596)
150. A.A. Farooqui, L.A. Horrocks, and T. Farooqui Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders Chem Phys Lipids 106 2000 1 29 (Pubitemid 30394588)
151. W.H. Vahidi, W.Y. Ong, A.A. Farooqui, and J.F. Yeo Pronociceptive effect of central nervous lysophospholipids in a mouse model of orofacial pain Exp Brain Res 174 2006 781 785
152. R.R. Ji, T. Kohno, K.A. Moore, and C.J. Woolf Central sensitization and LTP: do pain and memory share similar mechanisms? Trends Neurosci 26 2003 696 705 (Pubitemid 37415022)
153. J.F. Yeo, W.Y. Ong, S.F. Ling, and A.A. Farooqui Intracerebroventricular injection of phospholipases A2 inhibitors modulates allodynia after facial carrageenan injection in mice Pain 112 2004 148 155 (Pubitemid 39371030)
154. G. Raivich, M. Bohatschek, C.U. Kloss, A. Werner, L.L. Jones, and G.W. Kreutzberg Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function Brain Res Brain Res Rev 30 1999 77 105 (Pubitemid 29331517)
155. T. Schilling, F. Lehmann, B. Ruckert, and C. Eder Physiological mechanisms of lysophosphatidylcholine-induced de-ramification of murine microglia J Physiol (Lond.) 557 2004 105 120 (Pubitemid 38771640)
156. 2+ influx, pore formation and p44/42 MAP kinase phosphorylation mediated by P2X7 receptor activation in mouse microglial cells J Neurochem 102 2007 1518 1532 (Pubitemid 47256191)
157. J. Gehrmann, Y. Matsumoto, and G.W. Kreutzberg Microglia: intrinsic immuneffector cell of the brain Brain Res Brain Res Rev 20 1995 269 287
158. A.A. Farooqui, L. Liss, and L.A. Horrocks Elevated activities of lipases and lysophospholipases in Alzheimer's disease Dementia 1 1990 208 214
159. G. Tigyi, D.J. Fischer, A. Sebök, F. Marshall, D.L. Dyer, and R. Miledi Lysophosphatidic acid-induced neurite retraction in PC12 cells: neurite-protective effects of cyclic AMP signaling J Neurochem 66 1996 549 558
160. 2+ signaling and Rho J Neurochem 66 1996 537 548
161. F.W. Holtsberg, M.R. Steiner, K. Furukawa, J.N. Keller, M.P. Mattson, and S.M. Steiner Lysophosphatidic acid induces a sustained elevation of neuronal intracellular calcium J Neurochem 69 1997 68 75 (Pubitemid 27274157)
162. X. Ye, N. Fukushima, M.A. Kingsbury, and J. Chun Lysophosphatidic acid in neural signaling Neuroreport 13 2002 2169 2175 (Pubitemid 36044423)
163. W.H. Moolenaar, L.A. van Meeteren, and B.N. Giepmans The ins and outs of lysophosphatidic acid signaling Bioessays 26 2004 870 881 (Pubitemid 39128101)
164. B. Anliker, and J. Chun Cell surface receptors in lysophospholipid signaling Semin Cell Dev Biol 15 2004 457 465 (Pubitemid 38953942)
165. G.J. Ramakers, and W.H. Moolenaar Regulation of astrocyte morphology by RhoA and lysophosphatidic acid Exp Cell Res 245 1998 252 262 (Pubitemid 28565766)
166. G. Tigyi, L. Hong, M. Yakubu, H. Parfenova, M. Shibata, and C.W. Leffler Lysophosphatidic acid alters cerebrovascular reactivity in piglets Am J Physiol 268 1995 H2048 H2055
167. C. Schulze, C. Smales, L.L. Rubin, and J.M. Staddon Lysophosphatidic acid increases tight junction permeability in cultured brain endothelial cells J Neurochem 68 1997 991 1000 (Pubitemid 27086203)
168. + channels for lysophosphatidic acid-induced microglial migration Eur J Neurosci 19 2004 1469 1474 (Pubitemid 38437909)
169. Y. Xie, T.C. Gibbs, and K.E. Meier Lysophosphatidic acid as an autocrine and paracrine mediator Biochim Biophys Acta 1582 2002 270 281 (Pubitemid 34634139)
170. S. Okudaira, H. Yukiura, and J. Aoki Biological roles of lysophosphatidic acid signaling through its production by autotaxin Biochemie 92 2010 696 706
171. J. Chun Lysophospholipid receptors: implications for neural signaling Crit Rev Neurobiol 13 1999 151 168 (Pubitemid 29431428)
172. N. Fukushima, I. Ishii, J.J. Contos, J.A. Weiner, and J. Chun Lysophospholipid receptors Annu Rev Pharmacol Toxicol 41 2001 507 534 (Pubitemid 32385897)
173. C.L. Sayas, M.T. Moreno-Flores, J. Avila, and F. Wanddosell The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like Tau phosphorylation J Biol Chem 274 1999 37046 37052
174. C.L. Sayas, J. Avila, and F. Wandosell Regulation of neuronal cytoskeleton by lysophosphatidic acid: role of GSK-3 Biochim Biophys Acta 1582 2002 144 153 (Pubitemid 34634123)
175. S. Moriguchi, N. Shioda, Y. Yamamoto, and K. Fukunaga Platelet-activating factor-induced synaptic facilitation is associated with increased calcium/calmodulin-dependent protein kinase II, protein kinase C and extracellular signal-regulated kinase activities in the rat hippocampal CA1 region Neuroscience 166 2010 1158 1168
176. G. Goracci, M.L. Balestrieri, and V. Nardicchi Metabolism and functions of platelet-activating factor (PAF) in the nervous tissue Handbook of neurochemistry and molecular neurobiology 3rd ed. 2009 Springer Science + Media, LIC p. 311-352
177. E. Francescangeli, A. Boila, and G. Goracci Properties and regulation of microsomal PAF-synthesizing enzymes in rat brain cortex Neurochem Res 25 2000 705 713 (Pubitemid 30422005)
178. G. Goracci, and E. Francescangeli Properties of PAF-synthesizing phosphocholinetransferase and evidence for lysoPAF acetyltransferase activity in rat brain Lipids 26 1991 986 991
179. S.D. Ryan, S.N. Whitehead, L.A. Swayne, T.C. Moffat, W. Hou, and M. Ethier Amyloid-beta42 signals tau hyperphosphorylation and compromises neuronal viability by disrupting alkylacylglycerophosphocholine metabolism Proc Natl Acad Sci USA 106 2009 20936 20941
180. K. Kato, G.D. Clark, N.G. Bazan, and C.F. Zorumski Platelet-activating factor as a potential retrograde messenger in CA1 hippocampal long-term potentiation Nature 367 1994 175 179 (Pubitemid 24031698)
181. M. Mori, M. Aihara, K. Kume, M. Hamanoue, S. Kohsaka, and T. Shimizu Predominant expression of platelet-activating factor receptor in rat brain microglia J Neurosci 16 1996 3590 3600 (Pubitemid 26149497)
182. S.M. Prescott, G.A. Zimmerman, D.M. Stafforini, and T.M. McIntyre Platelet activating factor and related lipid mediators Annu Rev Biochem 69 2000 419 445
183. S.D. Ryan, C.S. Harris, C.L. Carswell, J.E. Baenziger, and S.A. Bennett Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons J Lipid Res 49 2008 2250 2258
184. P. Heusler, and G. Boehmer Platelet-activating factor contributes to the induction of long-term potentiation in the rat somatosensory cortex in vitro Brain Res 1135 2007 85 91 (Pubitemid 46176832)
185. C. Chen, J.C. Magee, V. Marcheselli, M. Hardy, and N.G. Bazan Attenuated LTP in hippocampal dentate gyrus neurons of mice deficient in the PAF receptor J Neurophysiol 85 2001 384 390 (Pubitemid 32062148)
186. I. Izquierdo, C. Fin, P.K. Schmitz, R.C. Da Silva, D. Jerusalinsky, and J.A. Quillfeldt Memory enhancement by intrahippocampal, intraamygdala, or intraentorhinal infusion of platelet-activating factor measured in an inhibitory avoidance task Proc Natl Acad Sci USA 92 1995 5047 5051
187. S. Ishii, and T. Shimizu Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice Prog Lipid Res 39 2000 41 82 (Pubitemid 30145442)
188. K. Nogami, Y. Hirashima, S. Endo, and A. Takaku Involvement of platelet-activating factor (PAF) in glutamate neurotoxicity in rat neuronal cultures Brain Res 754 1997 72 78 (Pubitemid 27170253)
189. F. Ogden, M.A. DeCoster, and N.G. Bazan Recombinant plasma-type platelet-activating factor acetylhydrolase attenuates NMDA-induced hippocampal neuronal apoptosis J Neurosci Res 53 1998 677 684 (Pubitemid 28423876)
190. P.K. Mukherjee, M.A. DeCoster, F.Z. Campbell, R.J. Davis, and N.G. Bazan Glutamate receptor signaling interplay modulates stress-sensitive mitogen-activated protein kinases and neuronal cell death J Biol Chem 274 1999 6493 6498 (Pubitemid 29111065)
191. H.A. Gelbard, H.S. Nottet, S. Swindells, M. Jett, K.A. Dzenko, and P. Genis Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin J Virol 68 1994 4628 4635 (Pubitemid 24183060)
192. J.N. Kanfer, G. Sorrentino, and D.S. Sitar Phospholipases as mediators of amyloid beta peptide neurotoxicity: an early event contributing to neurodegeneration characteristic of Alzheimer's disease Neurosci Lett 257 1998 93 96 (Pubitemid 28552896)
193. S. Watanabe, M. Doshi, K. Akimoto, Y. Kiso, and T. Hamazaki Suppression of platelet-activating factor generation and modulation of arachidonate metabolism by dietary enrichment with (n-9) eicosatrienoic acid or docosahexaenoic acid in mouse peritoneal cells Prostaglandins Other Lipid Mediat 66 2001 109 120 (Pubitemid 32781758)
194. J. Lu, M.S. Caplan, D. Li, and T. Jilling Polyunsaturated fatty acids block platelet activating factor-induced phosphatidylinositol 3 kinase/Akt-mediated apoptosis in intestinal epithelial cells Am J Physiol Gastrointest Liver Physiol 294 2008 1181 1190
195. G.M. Cole, and S.A. Frautschy Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model Nutr Health 18 2006 249 259 (Pubitemid 44844123)
196. A. Zembowicz, J.L. Tang, and K.K. Wu Transcriptional induction of endothelial nitric oxide synthase type III by lysophosphatidylcholine J Biol Chem 270 1995 17006 17010
197. M. Glass, M. Dragunow, and R.L. Faull Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain Neuroscience 77 1997 299 318 (Pubitemid 27079604)
198. T. Harkany, K. Mackie, and P. Doherty Wiring and firing neuronal networks: endocannabinoids take center stage Curr Opin Neurobiol 18 2008 338 345
199. J.S. Moody, K.R. Kozak, C. Ji, and L.J. Marnett Selective oxygenation of the endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase Biochemistry 40 2001 861 866 (Pubitemid 32108577)
200. K.R. Kozak, R.A. Gupta, J.S. Moody, C. Ji, W.E. Boeglin, and R.N. DuBois 15-Lipoxygenase metabolism of 2-arachidonoylglycerol. Generation of a peroxisome proliferator-activated receptor-α agonist J Biol Chem 277 2002 23278 23286 (Pubitemid 34952156)
201. V. Di Marzo Endocannabinoids: synthesis and degradation S.G. Amara, E. Bamberg, B.K. Fleischmann, T.H. Gudermann, S.C. Hebert, R. Jahn, W.J. Lederer, R. Lill, A. Miyajima, S. Offermanns, R. Zechner, Review of physiology biochemistry and pharmacology 2006 Springer Berlin, Heidelberg 1 24
202. M.A. Huestis, D.A. Gorelick, S.J. Heishman, K.L. Preston, R.A. Nelson, and E.T. Moolchan Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716 Arch Gen Psychiatry 58 2001 322 328 (Pubitemid 32299527)
203. G. Marsicano, S. Goodenough, K. Monory, H. Hermann, M. Eder, and A. Cannich CB1 cannabinoid receptors and on-demand defense against excitotoxicity Science 302 2003 84 88 (Pubitemid 37210691)
204. K. Maresz, E.J. Carrier, E.D. Ponomarev, C.J. Hillard, and B.N. Dittel Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli J Neurochem 95 2005 437 445 (Pubitemid 41457512)
205. C. Benito, E. Nunez, R.M. Tolon, E.J. Carrier, A. Rabano, and C.J. Hillard Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains J Neurosci 23 2003 11136 11141 (Pubitemid 37548949)
206. B.G. Ramirez, C. Blazquez, T. Gomez del Pulgar, M. Guzman, and M.L. de Ceballos Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation J Neurosci 25 2005 1904 1913 (Pubitemid 40289395)
207. G. Poli, and R.J. Schaur 4-Hydroxynonenal in the pathomechanisms of oxidative stress IUBMB Life 50 2000 315 321 (Pubitemid 32289090)
208. K. Uchida 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress Prog Lipid Res 42 2003 318 343 (Pubitemid 36411689)
209. G. Poli, F. Biasi, and G. Leonarduzzi 4-Hydroxynonenal-protein adducts: a reliable biomarker of lipid oxidation in liver diseases Mol Aspects Med 29 2006 67 71
210. H. Esterbauer, R.J. Schaur, and H. Zollner Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes Free Radic Biol Med 11 1991 81 128 (Pubitemid 121003917)
211. R.J. Schaur Basic aspects of the biochemical reactivity of 4-hydroxynonenal Mol Aspects Med 24 2003 149 159 (Pubitemid 36945015)
212. H. Raza, A. John, E.M. Brown, S. Benedict, and S. Kambal Alterations in mitochondrial respiratory functions, redox metabolism and apoptosis by oxidant 4-hydroxynonenal and antioxidants curcumin and melatonin in PC12 cells Toxicol Appl Pharmacol 226 2008 161 168
213. M. Guglielmotto, L. Giliberto, E. Tamagno, and M. Tabaton Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors Front Aging Neurosci 2 2010 3
214. M. Perluigi, R. Sultana, G. Cenini, F. Di Domenico, M. Memo, and W.M. Memo Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: role of lipid peroxidation in Alzheimer's disease pathogenesis Proteomics Clin Appl 3 2009 682 693
215. D.A. Butterfield, M.L. Bader Lange, and R. Sultana Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease Biochim Biophys Acta 1801 2010 924 929
216. M.A. Lovell, W.D. Ehmann, M.P. Mattson, and W.R. Markesbery Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease Neurobiol Aging 18 1997 457 461 (Pubitemid 27497140)
217. R. Wang, J.S. Malter, and D.S. Wang N-acetylcysteine prevents 4-hydroxynonenal- and amyloid-beta-induced modification and inactivation of Neprilysin in SH-SY5Y cells J Alzheimer Res 19 2010 179 189
218. J. Drake, R. Petroze, A. Castegna, Q. Ding, J.N. Keller, and W.R. Markebery 4-Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease Neurosci Lett 356 2004 155 158 (Pubitemid 38186675)
219. B.S. Kristal, B.K. Park, and B.P. Yu 4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition J Biol Chem 271 1996 6033 6038 (Pubitemid 26095405)
220. M.J. Picklo, V. Amarnath, J.O. McIntyre, D.G. Graham, and T.J. Montine 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites J Neurochem 72 1999 1617 1624 (Pubitemid 29140836)
221. M.A. Bradley, S. Xiong-Fister, W.R. Markesbery, and M.A. Lovell Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression Neurobiol Aging 2010 10.1016/j.neurobiolaging.2010.08.01
222. D.E. O'Connor, E.D. Mihelich, and M.C. Coleman Stereochemical course of the autooxidized cyclization of the lipid hydroperoxides to prostaglandine-like bicycloendoperoxizes J Am Chem Soc 106 1984 3577 3584 (Pubitemid 14609840)
223. J.D. Morrow, J.A. Awad, H.J. Boss, I.A. Blair, and L.J. Roberts 2nd Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids Proc Natl Acad Sci USA 89 1992 10721 10725
224. D.M. Stafforini, J.R. Sheller, T.S. Blackwell, A. Sapirstein, F.E. Yull, and T.M. McIntyre Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases J Biol Chem 281 2006 4616 4623 (Pubitemid 43847720)
225. S.S. Fam, and J.D. Morrow The isoprostanes: unique products of arachidonic acid oxidation - a review Curr Med Chem 10 2003 1723 1740 (Pubitemid 37038596)
226. S. Basu Metabolism of 8-iso-prostaglandin F2alpha FEBS Lett 428 1998 32 36
227. S. Basu Isoprostanes: novel bioactive products of lipid peroxidation Free Radical Res 38 2004 105 122 (Pubitemid 38181167)
228. T. Nishio, R. Miyadera, R. Sakai, K. Abe, H. Kanazawa, and K. Fukui Increased F-2-isoprostane levels in the rat brain and plasma caused by oxidative stress and aging, and inhibitory effect of vitamin E J Clin Biochem Nutr 38 2006 161 166 (Pubitemid 43761951)
229. L.J. Janssen Isoprostanes: an overview and putative roles in pulmonary pathophysiology Am J Physiol Lung Cell Mol Physiol 280 2001 L1067 L1082
230. E.S. Musiek, H. Yin, G.L. Milne, and J.D. Morrow Recent advances in the biochemistry and clinical relevance of the isoprostane pathway Lipids 40 2005 987 994
231. J.D. Morrow The isoprostanes: their quantification as an index of oxidant stress status in vivo Drug Metab Rev 32 2000 377 385 (Pubitemid 32001913)
232. L.J. Roberts 2nd, J.P. Fessel, and S.S. Davies The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation Brain Pathol 15 2005 143 148 (Pubitemid 40546170)
233. H. Scholz, A. Yndestad, J.K. Dams, T. Waehre, S. Tonstad, and P. Aukrust 8-Isoprostane increases expression of interleukin-8 in human macrophages through activation of mitogen-activated protein kinases Cardiovasc Res 59 2003 945 954 (Pubitemid 38366250)
234. I. Lahaie, P. Hardy, X. Hou, H. Hassessian, P. Asselin, and P. Lachapelle A novel mechanism for vasoconstrictor action of 8-isoprostaglandin F2α on retinal vessels Am J Physiol 274 1998 R1406 R1416
235. T.J. Montine, W.R. Markesbery, J.D. Morrow, and L.J. Roberts 2nd Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease Ann Neurol 44 1998 410 413 (Pubitemid 28421451)
236. T.J. Montine, E.R. Peskind, J.F. Quinn, A.M. Wilson, K.S. Montine, and D. Galasko Increased cerebrospinal fluid F(2)-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers Neuromolecular Med. 13 2011 37 43
237. R.J. Mark, K.S. Fuson, and P.C. May Characterization of 8-epiprostaglandin F2alpha as a marker of amyloid beta-peptide-induced oxidative damage J Neurochem 72 1999 1146 1153 (Pubitemid 29085030)
238. L. Brunetti, B. Michelotto, G. Orlando, L. Recinella, C. Di Nisio, and G. Ciabattoni Aging increases amyloid beta-peptide-induced 8-iso-prostaglandin F2alpha release from rat brain Neurobiol Aging 25 2004 125 129 (Pubitemid 37522200)
239. D. Pratico, K. Uryu, S. Leight, J.Q. Trojanoswki, and V.M. Lee Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis J Neurosci 21 2001 4183 4187 (Pubitemid 32538543)
240. D. Pratic The neurobiology of isoprostanes and Alzheimer's disease Biochim Biophys Acta 1801 2010 930 933
241. D.W. Shineman, B. Zhang, S.N. Leight, D. Pratico, and V.M. Lee Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice J Neurosci 28 2008 4785 4794
242. L.J. Roberts 2nd, T.J. Montine, W.R. Markesbery, A.R. Tapper, P. Hardy, and S. Chemtob Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid J Biol Chem 273 1998 13605 13612 (Pubitemid 28268404)
243. H.Y. Yin, E.S. Musiek, L. Gao, N.A. Porter, and J.D. Morrow Regiochemistry of neuroprostanes generated from the peroxidation of docosahexaenoic acid in vitro and in vivo J Biol Chem 280 2005 26600 26611 (Pubitemid 41022258)
244. A. Greco, and L. Minghetti Isoprostanes as biomarkers and mediators of oxidative injury in infant and adult central nervous system diseases Curr Neurovasc Res 1 2004 341 354
245. E.E. Reich, W.R. Markesbery, L.J. Roberts 2nd, L.L. Swift, J.D. Morrow, and T.J. Montine Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease Am J Pathol 158 2001 293 297 (Pubitemid 32096495)
246. L.J. Roberts 2nd, and J.P. Fessel The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation Chem Phys Lipids 128 2004 173 186 (Pubitemid 38167386)
247. O. Boutaud, K.I. Andreasson, I. Zagol-Ikapitte, and J.A. Oates Cyclooxygenase-dependent lipid-modification of brain proteins Brain Pathol 15 2005 139 142 (Pubitemid 40546169)
248. C.J. Brame, O. Boutand, S.S. Davies, T. Yang, J.A. Oates, and D. Roden Modification of proteins by isoketal-containing oxidized phospholipids J Biol Chem 279 2004 13447 13451 (Pubitemid 38468868)
249. S.S. Davies, V. Amarnath, and L.J. Roberts 2nd Isoketals: highly reactive γ-ketoaldehydes formed from the H2-isoprostane pathway Chem Phys Lipids 128 2004 85 99 (Pubitemid 38167379)
250. O. Boutaud, J.J. Ou, P. Chaurand, R.M. Caprioli, T.J. Montine, and J.A. Oates Prostaglandin H2 (PGH2) accelerates formation of amyloid beta1-42 oligomers J Neurochem 82 2002 1003 1006
251. C.B. Sullivan, E. Matafonova, L.J. Roberts 2nd, V. Amarnath, and S.S. Davies Isoketals form cytotoxic phosphatidylethanolamine adducts in cells J Lipid Res 51 2010 999 1009
252. N. Bernoud-Hubac, S.S. Davies, O. Boutaud, T.J. Montine, and L.J. Roberts 2nd Formation of highly reactive gamma-ketoaldehydes (neuroketals) as products of the neuroprostane pathway J Biol Chem 276 2001 30964 30970
253. J.P. Fessel, N.A. Porter, K.P. Moore, J.R. Sheller, and L.J. Roberts 2nd Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension Proc Natl Acad Sci USA 99 2002 16713 16718 (Pubitemid 36034038)
254. J.P. Fessel, C. Hulette, S. Powell, L.J. Roberts 2nd, and J. Zhang Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson's disease and with dementia with Lewy body disease J Neurochem 85 2003 645 650 (Pubitemid 36531927)
255. W.L. Song, J.A. Lawson, D. Reilly, J. Rokach, C.T. Chang, and B. Giasson Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid J Biol Chem 283 2008 6 16
256. M.J. Picklo, and T.J. Montine Acrolein inhibits respiration in isolated brain mitochondria Biochim Biophys Acta 1535 2001 145 152 (Pubitemid 32114142)
257. J. Lou, and R. Shi Acrolein induces oxidative stress in brain mitochondria Neurochem Int 46 2005 243 252
258. M.A. Lovell, C. Xie, and W.R. Markesbery Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures Free Radic Biol Med 29 2000 714 720
259. N.Y. Calingasan, K. Uchida, and G.E. Gibson Protein-bound acrolein: A novel marker of oxidative stress in Alzheimer's disease J Neurochem 72 1999 751 756 (Pubitemid 29055239)
260. H. Aybek, F. Ercan, D. Aslan, and T. Sahiner Determination of malondialdehyde, reduced glutathione levels and APOE4 allele frequency in late-onset Alzheimer's disease in Denizli, Turkey Clin Biochem 40 2007 172 176 (Pubitemid 46108698)
261. D.T. Nam, M. Arseneault, V. Murthy, and C. Ramassamy Potential role of acrolein in neurodegeneration and in Alzheimer's disease Curr Mol Pharmacol 3 2010 66 78
262. K.R. Sidell, K.S. Montine, M.J. Picklo Sr., S.J. Olsen, V. Amarnath, and T.J. Montine Mercapturate metabolism of 4-hydroxy-2-nonenal in rat and human cerebrum J Neuropathol Exp Neurol 62 2003 146 153 (Pubitemid 36176949)
263. A.K. Mantha, K. Moorthy, S.M. Cowsik, and N.Z. Baquer Neuroprotective role of neurokinin B (NKB) on beta-amyloid (25-35) induced toxicity in aging rat brain synaptosomes: Involvement in oxidative stress and excitotoxicity Biogerontology 7 2006 1 17 (Pubitemid 44026968)
264. A.D. Cash, G. Perry, O. Ogawa, A.K. Raina, X. Zhu, and M.A. Smith Is Alzheimer's disease a mitochondrial disorder? Neuroscientist 8 2002 489 496
265. P.H. Reddy, and M.F. Beal Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev 49 2005 618 632 (Pubitemid 41546661)
266. A. Nunomura, G. Perry, G. Aliev, K. Hirai, A. Takeda, and E.K. Balraj Oxidative damage is the earliest event in Alzheimer disease J Neuropathol Exp Neurol 60 2001 759 767 (Pubitemid 32678256)